Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Indiana University
National Institutes of Health Clinical Center (CC)
AbbVie
AbbVie
AbbVie
Central European Society for Anticancer Drug Research
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
AbbVie
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AbbVie
National Cancer Institute (NCI)
AbbVie
AbbVie
AbbVie
National Cancer Institute (NCI)
AbbVie
AbbVie
AbbVie
AbbVie
AbbVie
Vanderbilt-Ingram Cancer Center
University of Washington
National Institutes of Health Clinical Center (CC)
AbbVie
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)